SLC9/NHE gene family, a plasma membrane and organellar family of Na+/H+ exchangers *

Mark Donowitza,*, C. Ming Tsea, and Daniel Fusterb

aDepartments of Medicine and Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States bDepartment of Nephrology and Hypertension, GNI Institute of Biochemistry and Molecular Medicine, University Hospital of Bern, Switzerland

Abstract

This brief review of the human Na/H exchanger gene family introduces a new classification with three subgroups to the SLC9 gene family. Progress in the structure and function of this gene family is reviewed with structure based on homology to the bacterial Na/H exchanger NhaA. Human diseases which result from genetic abnormalities of the SLC9 family are discussed although the exact role of these transporters in causing any disease is not established, other than poorly functioning NHE3 in congenital Na diarrhea

Keywords

SLC9; Na/H exchanger gene family; Antiporter; 1:1 stoichiometry; Na absorption; Intracellular pH

1. Introduction

This gene family is involved in pH homeostasis of the cytosol and intracellular organelles, is the major way Na+ is absorbed in the kidney and GI tract and includes isoforms that cycle between the plasma membrane and intracellular organelles as well as those that are static in the plasma membrane and perhaps in intracellular organelles. In addition, it is beginning to be apparent that the members of this gene family contribute to the pathophysiology of multiple human diseases. This brief review is an attempt to summarize current progress in all these areas for this diverse gene family.

The human Na+/H+ exchangers (Table 1) are encoded by the SLC9 gene family of the Solute Carrier classification of transporters (SLC, HUGO nomenclature, http://www.genenames.org) and are a subgroup of the eukaryotic and prokaryotic monovalent cation proton antiporter (CPA) superfamily (Transport Protein database http://tcdb.ucsd.edu/tcdb/) (Brett et al., 2005b; Orlowski and Grinstein, 2004). SLC9 has three subfamilies (Fig. 1): SLC9A: Na+/H+ antiporters (nine family member paralogs in the human genome, SLC9A1–9, encoding NHE1–9 with one established (NHE6) and one possible (NHE1) splice variant and five pseudogenes). SLC9B: SLC9B1 and SLC9B2 encoding NHA1 and NHA2 respectively, with NHA1 having a splice variant. SLC9C: SLC9C1 encodings perm
NHE, and \textit{SLC9C2}. Subfamily A is part of CPA1 (transporter classification database = TC 2A 36. 1–9), B is part of CPA2, and C is part of NaT-DC (Na-transporting carboxylic acid decarboxylase) with the SLC9C members of NaT-DC being questionable members since they do not cluster with other mammalian NHEs and only weakly associate with other members of the NaT-DC gene family (Brett et al., 2005b). The evolution of this gene family has been described in detail (Brett et al., 2005b; Orlowski and Grinstein, 2004).

2. \textbf{SLC9 structure (Fig. 2)}

The structure has not been solved for any member of the SLC9 family. However, a great deal of structural information is known. All NHEs are organized in a similar fashion with an \textasciitilde450 aa N-terminus being made up of 11 or 12 membrane spanning domains and carrying out the Na\textsuperscript{+} and H\textsuperscript{+} exchange and the varying length intracellular C-terminal domain (~125–440 amino acids, based on the isoform) being involved in regulation of the exchange activity (Table 1; Donowitz et al., 2009). There is evidence that the C-terminus associates with both intracellular aspects of the N-terminus and also with the inner leaflet of the plasma membrane via interactions with negatively charged phospholipids (PS, PIP2, PIP3) (Ikeda et al., 1997; Alexander et al., 2011). In spite of the SLC9 structures not having been directly solved, based on homology modeling using the solved structure of the \textit{E. coli} Na\textsuperscript{+}/H\textsuperscript{+} antiporter NhaA (Hunte et al., 2005; Padan et al., 2009), the general view is that the basic structure of the SLC9 transport domain is known. Specifically bioinformatic analyses with use of fold alignment algorithms supplemented with some mutagenesis studies of NHE1 and NHA2 have been performed in spite of the amino acid alignment of NhaA and the SLC9 members being \textasciitilde10\% (Landau et al., 2007; Schushan et al., 2010). In addition, structural information has been gained via study of NHE1 using cysteine scanning mutagenesis formed on cysteine-less mutants (Wakabayashi et al., 2000). These two approaches have not led to identical models and we describe our interpretations of an ongoing area of research. The transport of Na\textsuperscript{+} and H\textsuperscript{+} in the NHEs occurs in the center of the N-terminus via a two inverted funnel area that is made up of two transmembrane helices which in some cases cross each other and contain charged residues forming dipoles that are modified by surrounding oppositely charged residues. This area undergoes conformational changes in the transport cycles and carries out the Na\textsuperscript{+} and H\textsuperscript{+} exchange. This funnel organization for the transport function is now known to be used by at least 12 gene families (sodium-dependent bile acid cotransporter encoded by \textit{SLC10A2} and, SGLT1 encoded by \textit{SLC5A1}, among others) and may be the generally used organization of the transport domain of co-transporters and antiporters (Nien-Jen et al., 2011). The structure in addition contains a pH sensor which is involved in the role of regulation of the exchange function by intracellular H\textsuperscript{+} in addition to the transport of protons, which is structurally separate from the transport funnel and a dimerization domain (Padan et al., 2009). All SLC9 members appear to exist as dimers and while transport function occurs as a monomer, the dimerization is believed to provide stability of the molecule. The major difference in interpretation of the SLC9 structure from the two approaches relates to the N-terminal membrane spanning domains. What is considered membrane spanning domains 1 and 2 by the cysteine scanning mutagenesis approach is felt by homology to NhaA not to be membrane spanning domains at all. This domain does not appear to be important for any NHE function and has been suggested as being cleaved off, including via the presence of putative signal sequences for some NHEs.

3. \textbf{SLC9A/NHE family}

3.1. \textit{Slc9a1} – NHE1

The human NHE1 protein, encoded by \textit{SLC9A1}, is 815 amino acids long and contains a hydrophobic N-terminal membrane domain of 500 amino acids responsible for NHE
transport and a hydrophilic, intracellular 315 amino acid long C-terminus that is necessary for NHE1 regulation. Plasmamembral NHE1 is both N- and O-glycosylated, but glycosylation is not required for transport function. NHE1 is highly sensitive to amiloride and is also sensitive to lipophilic amiloride derivatives including ethylisopropylamiloride (EIPA) and the benzyloxyguanidines HOE694 and cariporide.

NHE1 is present in most mammalian cells. Exceptions lacking NHE1 are macula densa and α- and β-intercalated cells of the kidney. NHE1 resides almost exclusively on the surface of cells, but in some cells preferentially accumulates in discrete microdomains of the plasma membrane. In polarized epithelial cells, NHE1 localizes to the basolateral membrane, in cardiac myocytes to intercalated disks and T-tubules and in resting fibroblasts to sites of focal adhesions. In contrast, in migrating fibroblasts, NHE1 concentrates at the leading edge of the cell along the border of lamellipodia. NHE1 abundance at the plasma membrane is regulated by its ubiquitination (Simonin and Fuster, 2010)

NHE1 serves as an important alkalinizing mechanism of the cell in defense of H^+ derived from metabolism or electrically-driven H^+-accumulation. In addition, NHE1 constitutes a major pathway for Na^+ influx into the cell and when coupled to Cl^- and H_2O uptake, it represents a mechanisms for restoration of cell volume following cell shrinkage. In specialized secretory cell types like acinar cells of parotid or sublingual glands, NHE1 is necessary for secretagogue-induced fluid secretion. The unique subcellular localization of NHE1 in certain cell types suggests that NHE1 has additional biological functions. For instance, in cardiac myocytes, the specific localization of NHE1 to intercalated disks and T-tubules but not the peripheral sarcolemmal membranes is thought to affect local pH, thereby influencing the activity of pH-sensitive proteins, such as the gapjunction protein connexin43 and the ryanodine-sensitive Ca^{2+} release channel. NHE1 is also involved in cell migration (Denker et al., 2000). Inhibition or genetic ablation of NHE1 in fibroblasts significantly reduces migration speed and deranges chemotaxis. Both ion translocation and anchoring of cytoskeletal proteins through the intracellular NHE1 C-terminus were shown to be necessary in this process. However, these effects appear to be cell specific; for instance, inhibition of NHE1 in granulocytes does not alter chemotaxis and chemokinesis (Hayashi et al., 2008). Furthermore, NHE1 knock-out mice exhibit normal embryogenesis (Bell et al., 1999; Cox et al., 1997).

The phenotype of two different Slc9a1 knock-out mice has been reported. One is a spontaneous mutation (“swe” – slow-wave epilepsy) that arose in the Jackson laboratories which resulted in a truncation of the protein in the transmembrane domain with a subsequent NHE1-null phenotype (Cox et al., 1997). The second Slc9A1 knock-out was engineered by homologous recombination resulting in deletion of NHE1 transmembrane domains 6 and 7 (Bell et al., 1999). Loss of NHE1 was compatible with embryogenesis but knock-out mice exhibited a decreased rate of postnatal growth and high mortality with ~10% of mice surviving at 5 weeks after birth (Bell et al., 1999). In addition, mice suffered from ataxia and epileptic seizures. This phenotype was associated with selective neuronal death in the cerebellum and brainstem of knock-out mice (Cox et al., 1997). Knock-out of Slc9A1 affected hippocampal and cortical cells by decreasing steady-state pH_i, attenuating pH_i recovery from cell acidification (even in the presence of HCO_3^-) and increasing expression and current density of voltage-gated Na^+ channels (Gu et al., 2001; Xia et al., 2003). Thus, loss of NHE1 seems to alter expression and activity of other membrane transport proteins in the brain, resulting in increased neuronal excitability.

Enhanced NHE1 activity can cause substantial intracellular Na^+ accumulation, that, through the activity of the plasmalemmal Na^+/Ca^{2+} exchanger, induces a deleterious increase of intracellular Ca^{2+} that ultimately leads to cell death (Karmazyn, 1988). Genetic ablation

*Mol Aspects Med.* Author manuscript; available in PMC 2013 July 26.
pharmacologic inhibition of NHE1 during episodes of ischemia–reperfusion mitigated cardiac and neural injuries both in vivo and in vitro in rodents and pigs (Lazdunski et al., 1985), with the mechanism presumably being less Na$^+$ driven intracellular Ca$^{2+}$ accumulation. Clinical trials in humans, however, have not been promising with no overall benefit of NHE1 inhibition by cariporide in acute coronary syndromes and no benefits in patients with acute myocardial infarction. NHE1 over-activity has also been linked to cardiac hypertrophy and heart failure. Wakabayashi developed a transgenic mouse that selectively overexpressed a constitutively active NHE1 in the heart (Nakamura et al., 2008). Increased NHE1 activity was sufficient to induce cardiac hypertrophy and ultimately heart failure in these transgenic mice.

The earliest evidence that NHE1 plays a role in the pathogenesis of cancer came from the studies of Pouyssegur and coworkers. In athymic nude mice, CCL39 hamster lung fibroblasts deficient in NHE1 caused tumors less frequently than wild-type cells with functional NHE1 (Lagarde et al., 1988). Since these initial observations, numerous studies have addressed the role of NHE1 in cancer. NHE1-dependent intracellular alkalization seems to play an important role in the development of a transformed phenotype, which can be prevented by NHE1 inhibition (Reshkin et al., 2000b). In breast cancer and leukemic cells, inhibition of NHE1 exerts a protective effect against cancer, inducing apoptosis. In breast cancer cells, serum deprivation activates NHE1 to induce cell motility and invasion (Reshkin et al., 2000a). The protons extruded by NHE1 at the cell front create an acidic environment optimal for the activity of proteinases involved in the degradation of extracellular matrix. Low pH also enhances cell-matrix interactions and cell adhesion at the front. Thus, NHE1 seems to promote tumorigenesis at several levels, including cell proliferation, cell migration, invasion, metastasis and suppression of apoptosis. However, there is no evidence that inhibition of NHE1 is useful in treatment of cancer in humans.

NHE1 takes part in forming signaling complexes on its C-terminus (Baumgartner et al., 2004). NHE1 is regulated by phosphoinositides, posttranslational modifications in the NHE1 C-terminus (phosphorylation, ubiquitylation) and binding proteins. The Ca$^{2+}$-binding protein calmodulin was one of the first NHE1-binding proteins identified, and the crystal structure of the NHE1 – calmodulin complex was reported recently (Koester et al., 2011) Calmodulin binds to two sites in the NHE1 C-terminus: a high affinity site (amino acids 636–656) and a low affinity site (amino acids 657–700). In the absence of calmodulin, the high affinity binding site of NHE1 interacts with another region of NHE1, most likely the protonmodifier site in the transmembrane domain, acting in an autoinhibitory manner. In the presence of increased intracellular Ca$^{2+}$ and calmodulin, this interaction is released and activation of NHE1 ensues. In support of this model, deletion of the calmodulin high affinity binding site on the NHE1 C-terminus renders NHE1 constitutively active.

Calcineurin homologous protein (CHPs 1–3) is another well studied NHE1-binding protein that was originally identified by screening an expression library with the NHE1 C-terminus. CHP1 is cytosolic, myristoylated and binds Ca$^{2+}$ and interacts with a hydrophobic cluster of residues in the NHE1 proximal C-terminus located between amino acids 510 and 530. CHP1 is an obligatory binding partner of NHE1 (and also of NHE2 and NHE3). NHE1 or CHP1 mutants that interfere with the interaction result in a dramatic loss of NHE1 activity and NHE1 protein at the plasma membrane. CHP2 has 61 % amino acid identity to CHP1 and binds to the same juxtamembranous region on the NHE1 C-terminus. CHP2 is highly expressed only in the intestine and in tumor cells and protects cells from serum deprivation-induced cell death by activating NHE1 and increasing cell pH. The crystal structure of CHP2 in conjunction with the juxtamembranous portion of the NHE1 C-terminus was solved recently (Ben et al., 2005; Mishima et al., 2007).
NHE1 transport requires ATP and cellular ATP depletion inhibits NHE1 activity. This is largely the result of cellular depletion of PIP\(_2\). As intracellular ATP levels fall, plasmalemmal PIP\(_2\) levels diminish concomitantly (Aharonovitz et al., 2000). Sequestration or hydrolysis of plasmalemmal PIP\(_2\), in the absence of cellular ATP depletion, is associated with profound inhibition of NHE1 activity. In contrast, NHE1 function in ATP-depleted cells can be restored by direct perfusion of PIP\(_2\) into the cell. NHE1 contains two C-terminal juxtamembrane stretches of positively charged amino acids that bind PIP\(_2\) \textit{in vitro} (Aharonovitz et al., 2000). Mutation of these two sites greatly reduces NHE1 activity and PIP\(_2\) binding. The underlying mechanisms by which PIP\(_2\) affects NHE1 activity remain unknown. ATP, however, is also consumed during protein phosphorylation by kinases. Sardet et al. first demonstrated that NHE1 was a phosphoprotein (Sardet et al., 1990). Tryptic phosphopeptide mapping revealed that NHE1 was phosphorylated on serine and threonine but not tyrosine residues in response to growth factors. All relevant \textit{in vivo} phosphorylation sites map to the NHE1 C-terminal 636–815 amino acids. However, deletion of these sites resulted in only a ~50% loss of the growth factor stimulatory effect on NHE1 activity, suggesting that activation of NHE1 by growth factors occurs via additional mechanisms that do not require its direct phosphorylation. Kinases involved in NHE1 phosphorylation include: Calmodulin-dependent kinase II (CaM kinase II), extracellular-regulated kinases 1 and 2 (ERK1/2), ribosomal protein S6 kinase (p90\textsuperscript{RSK}), p160\textsuperscript{ROCK}, Nck-interacting kinase (NIK). Oppositely, dephosphorylation of NHE1 is carried out by protein phosphatases PP1 and PP2a, and prevention of de-phosphorylation by inhibition of phosphatases maintains NHE1 in an active state.

A recently identified NHE1 splice variant is a Na\(^+\)/Li\(^+\) and not a Na\(^+\)/H\(^+\) exchanger. The functional relevance of this protein has not been established and NHA2 also carries out Na\(^+\)/Li\(^+\) exchange.

### 3.2. Slc9a2 – NHE2

NHE2 is an epithelial Na\(^+\)/H\(^+\) exchanger, encoded by the \textit{SLC9A2} gene, that has 812 amino acids and is in the brush border of the small intestine, colon and gallbladder but in the basolateral membrane of stomach and is also in endothelial cells where it contributes to forming the blood brain barrier (Tse et al., 1993; Wang et al., 1993; Hoogerwerf et al., 1996). It is present in the kidney, in the apical domain of the thick ascending limb of Henle and the distal convoluted tubules.

Physiologically, the functional role of NHE2 is not established, although it is involved in some intestinal and renal Na absorption and there is recent evidence that it has a role in repair of epithelial damage (Xue et al., 2011). In cell systems, it is primarily present in the brush border, is not regulated by trafficking except potentially for its stimulation by short chain fatty acids, and unlike NHE3 its activity is not PI 3-kinase dependent. The location of NHE2 is in the brush border (BB) of villous cells and upper crypt cells of human small intestine and surface cells of the proximal and distal colon and sigmoid with its major expression in the distal colon. In the mouse colon, it is also in the crypt cell BB. \textit{Slc9a2} KO mice have no intestinal phenotype with \textit{Slk9a2}\textsl{Slc9a2} double knock out being similar to \textit{Slk9a2} KO. The contribution of NHE2 to intestinal Na\(^+\)/H\(^+\) exchange activity varies based on species. In rabbit ileum, half of NHE activity is due to both NHE3 and NHE2; in rat small intestine, NHE2 only accounts for 1/3 of the NHE activity and NHE2 does not contribute to canine ileal basal or post-prandial Na absorption. Similarly, NHE2 contributes only 10% to rat proximal colon NHE activity, and 25% to distal colon (Hoogerwerf et al., 1996), but it accounts for almost all chicken colonic NHE activity. Acute NHE2 regulation has not been thoroughly studied, although in Caco-2 cells, NHE2 is inhibited by cAMP and elevated Ca\(^{2+}\) (including by serotonin), stimulated by serum and not affected by cGMP and PKC; results in response to hyperosmolarity are contradictory with both inhibition and
stimulation reported. In a model of enteropathogenic E. coli (EPEC) related diarrhea in Caco-2 cells, NHE2 was inhibited and NHE2 is also inhibited by cholera toxin in rat ileum (Hecht et al., 2004). In colon NHE2 is linked to a short chain fatty acid/HCO$_3^-$ exchanger which is inhibited by cAMP but the inhibition is reversed by luminal butyrate (Subramanya et al., 2007). It is possible that the role of NHE2 in epithelial repair is a major function. Parietal cells are missing in Slc9a2 KO mice consistent with NHE2 being involved in preventing or responding to damage (Schultheis et al., 1998a,b). In mouse intestine, the presence of NHE2 increased recovery in ischemia related altered tight junction function and in mouse gastric epithelium, recovery from damage was NHE2 dependent, including that mediated by Trefoil factor 2 (Xue et al., 2011). There are no structural studies of NHE2 and no diseases described caused by its defective function. In Slc9a2 KO mice, there is increased renal renin content, even though the animals do not appear to be dehydrated. This suggests a role for NHE2 in signal transduction regulating renin expression.

3.3. Slc9a3 – NHE3

NHE3, which contains 834 amino acids in man (Brant et al., 1995), is encoded by the SLC9A3 gene and is an example of the NHE isoforms which continually traffic between the recycling system and the plasma membrane with their major function being in the plasma membrane (Janecki et al., 1998; Chow et al., 1999). NHE3 is thus most related to NHE5 and dissimilar to the intraorganellar NHEs which oppositely have their major function in the organellar membranes (Brett et al., 2005a). NHE3 is present in the Na absorptive cells of the mammalian small intestine, colon, gall bladder, renal proximal tubule, and thick and thin limbs of the loop of Henle (Hoogerwerf et al., 1996). It is present in gastric parietal cells either on the basolateral membrane (BLM) or apically based on species. It is also present in the epididymis, ovary, thymus, prostate, in some respiratory neurons in the ventrolateral medulla oblongata and in the most rostral extension of the retrotrapezoid nucleus/parapyramidal region in the pons. NHE3 is responsible for the majority of intestinal and renal Na absorption taking part in proximal, low efficiency-high capacity systems called neutral NaCl absorption (Zachos et al., 2005). In this process, NHE3 is linked to members of the SLC26A family of Cl/HCO$_3^-$ exchangers, particularly DRA (SLC26A3) and to an unclear extent PAT-1 (SLC26A6) as well (Jacob et al., 2002). The linkage is indirect via changes in pH but since both NHE3 and DRA bind multiple members of the NHERF family of multiple PDZ domain proteins, potentially via the physical linkage of NHE3 and DRA as well. In intestinal Na absorptive cells, nutrient (D-glucose and D-galactose, L-amino acid) related Na absorption and neutral NaCl absorption had been thought to be independent processes (Zachos et al., 2005). However, it is now known that D-glucose, acting via SGLT1 (SLC5A1), increases NHE3 trafficking to the BB of intestinal Na absorptive cells (Turner and Black, 2001; Lin et al., 2011). In this, SGLT1 uptake of D-Glu initiates an apical signaling cascade that includes p38 MAP kinase, MAP kinase kinase, PI3-K, AKT2, ezrin, and NHERF2 to increase NHE3 exocytosis. This linkage, along with changes in tight junctional permeability, is likely to contribute to the stoichiometry of Na to glucose absorption seen with oral rehydration solution (ORS) being higher than that of SGLT1 (2 Na:1 D-gluc). Importantly, the D-glucose stimulation of NHE3 reversed cholera toxin inhibition of NHE3 indicating that treatment of acute diarrhea could use ORS reversal of NHE3 inhibition to allow NHE3 to be a drug target for further stimulation of NHE3 activity (Lin et al., 2011). In the intestine, NHE3 regulation occurs acutely as part of digestion, and in the kidney changes occur largely as part of total body volume homeostasis. The time frame of regulation appears to be faster as part of digestion, although short term, intermediate and long term regulation occurs in both intestine and kidney. In the intestine, NHE3 is inhibited in the immediate post-prandial period, which probably helps to spread the digestive enzymes over the digestive/absorptive surface as part of the digestive process.
Later in digestion, there is stimulation of NHE3 which probably helps prevent dehydration as part of digestion.

The involvement of NHE3 in respiration is not well defined but inhibiting NHE3 seems to lower the apneic threshold and activates the central respiratory response to CO2, while increasing expression lowers the respiratory drive (Wiemann et al., 1999).

NHE3 trafficks between the brush border and recycling system and in the latter contributes to acidification. How this function interacts with the organellar V-ATPase is not known.

NHE3 is one of the most regulated of transport proteins with regulation occurring acutely, as well as on both an intermediate and long term basis including circadian regulation (Donowitz and Li, 2007). Rat colonic NHE3 undergoes diurnal variation which is maximum at midnight, a time of rodent eating (Sotak M. et al., 2011). Detailed reviews of second messenger and ligand regulation of NHE3 have been reported (Zachos et al., 2005; Donowitz and Li, 2007; Bobulescu and Moe, 2006). Acute regulation largely occurs by changes in rates of endocytosis and exocytosis which set the percent of NHE3 on the plasma membrane under basal conditions, although changes in NHE3 plasma membrane half-life have been documented. Of note, changes in the K′ (H+)i occur as well with acute changes in NHE3 activity, either alone or as part of NHE3 regulation as part of changes in trafficking. Endocytosis of NHE3 occurs by clathrin, lipid raft, and CDC42 dependent mechanisms, although why there is such complexity is not understood (Chow et al., 1999; Janecki et al., 1998; Li et al., 2001; Zachos et al., 2009). An additional aspect of acute regulation of NHE3 was recently defined in epithelial cells as a component of acute NHE3 stimulation and inhibition by changes in trafficking. This appears to have developed to deal with NHE3 being fixed to the microvillar cytoskeleton under basal conditions, which occurs via linking of NHE3 to the microvillar actin cytoskeleton by direct binding to ezrin plus by indirect binding to ezrin which occurs by ezrin binding to NHERF1 and NHERF2, with the latter two being NHE3 binding proteins. Acute stimulation of NHE3 by α-glucose and LPA and inhibition by elevated intracellular Ca2+ and cAMP are associated with dynamic and transient increased mobility in the microvillus of NHE3 which correlates with reduced binding to NHERF2 but not NHERF1 (Lin et al., 2011; Zhu et al., 2011). This dynamic association of NHE3 with the microvillar cytoskeleton allows NHE3 that is delivered to the BB as part of stimulated exocytosis to be spread over the microvillus; and also to gather microvillar NHE3 to take part in stimulated endocytosis.

The NHE3 C-terminus is necessary for its regulation. In this regulation, the NHE3 C-terminus acts as a scaffold binding multiple proteins and phosphoinositides that regulate it. To date the NHE3 regulatory proteins and lipids which directly bind the NHE3 C-terminus include CHP, ezrin, PIP2 and PIP3, CaMKII, CaM, PLC, IRBIT, megalin (Donowitz et al., 2009; He et al., 2008). The number of NHE3 associating proteins is almost certainly to have been only partially defined, given that the size of NHE3 complexes based on 5–60% sucrose density gradients is 1000–2000 kDa. Two major signaling complexes in the NHE3 C-terminus have been identified, both of which form at the sites at which NHE3 associates with the actin cytoskeleton, one the site of direct ezrin binding which appears involved in stimulation of NHE3 activity, and one at the site of the binding to the cytoskeleton via ezrin which occurs by ezrin-NHERF 1 or 2 binding, which is involved primarily in inhibition of NHE3 activity (Donowitz et al., 2008; Cha et al., 2006). The major NHE3 signaling complex defined till now appears involved in the post-prandial inhibition of NHE3 activity, which appears to be the major function of NHE3 in the intestine. This complex includes NHERF1–4, two kinases, one of which stimulates NHE3 (CK2) and one of which inhibits NHE3 (CaMKII) under basal conditions, PLC and potentially IRBIT and CaM. Multiple other protein–protein interactions affect NHE3 activity (for example, BetaPix-Shank2; etc.)
The complexity of NHE3 regulation in the apical domain is indicated by multiple pools of NHE3 being identified in both the brush border and intracellularly. These have been defined in multiple ways and the degree of overlap is largely unknown: brush border NHE3 is partially in lipid rafts, but also in a detergent soluble pool, partially bound to megalin, active or inactive, immobile (bound to NHERF proteins; separately Rho GTPase dependent) or easily mobilized (bound to NHERF2) and affected by changes in membrane curvature; while part of intracellular NHE3 is active and part can be divided into that rapidly or more slowly able to be mobilized for stimulated exocytosis (Alexander et al., 2007). The cytoskeleton is involved in NHE3 regulation in multiple ways. In epithelial cells, NHE3 is fixed to the microvillar actin cytoskeleton dynamically via direct and indirect binding to ezrin as described above. For trafficking in epithelial cells, endo and exocytosis of NHE3 must move NHE3 through the actin mesh in the terminal web (larger in intestinal than renal epithelial cells), an affect which involves myosin VI. Clostridium difficile toxin B dissociates NHE3 from the epithelial cell actin cytoskeleton and leads to its internalization as does inhibition of Rho-kinase, while in non-polarized cells, the actin cytoskeleton is necessary for basal NHE3 activity, by affecting turnover number, and cytoskeletal reorganization appears to be needed for non-trafficking related inhibition by cAMP elevation (Hayashi et al., 2004).

The ~377 aa C-terminus of NHE3 is predicted to have a structure with multiple helical domains predicted in the domains closest to the N-terminal transport domain. One of these domains, NHE3 amino acids 473–497 is highly homologous to a domain in the NHE1 C-terminus (amino acids 516–540) for which the structure has been solved when bound to CHP2 (calcineurin homologous protein) (Ammar et al., 2006). This domain is α-helical and is intimately intertwined with CHP.

Linkage of SLC9A3 to human diseases is limited, although animal models suggest likely clinical implications. Slc9a3 KO mice have mild diarrhea, increased water in the intestinal lumen and markedly increased mortality when placed on a low Na diet (Schultheis et al., 1998a,b). While the blood pressure of these mice is reduced, it can be normalized by increasing dietary Na content. A distal colitis has been identified in Slc9a3 null mice (Woo et al., 2002). This was not seen by the group which produced this mouse but was identified when the same mouse was housed in a different institution. This strongly suggests involvement of changes in the intestinal microbiome. INF was increased in small intestine but not colon of NHE3 null mice, without distal colitis. In contrast, in mice with the NHE3 null related colitis, there was increased severity of DSS induced colitis and appearance of a small intestinal enteritis which is not seen as part of DSS colitis in wild type mice (Kiela et al., 2009). In these mice, oral antibiotics reduced INF expression to basal levels and delayed some of the increased mortality from DSS, again supporting the role of the microbiome in the increased intestinal inflammation seen in the absence of NHE3. While absence of NHE3 influences inflammation and the inflammatory response in the intestine, intestinal inflammation also seems to alter NHE3 activity. NHE3 activity was reduced in the colonic crypts of patients with ulcerative colitis. Concerning mechanism of this reduced NHE3 activity, NHE3 is one of multiple intestinal transport proteins and their regulators which are down regulated in IBD, although there is controversy about whether this is due to changes in mRNA or protein or regulation involving changes in turnover number. In sigmoid colon biopsies from patients with Crohn’s disease and ulcerative colitis, based on immunoblotting, there was decreased amounts of NHE3 (as well as NHE1, -ENaC, NHERF1, CLC-5 and Na-K-ATPase subunit) and in mouse colon from DSS and TNBS-colitis there was reduced NHE3 (and NHE1, -ENaC and NHERF1 and NHERF2)(Sullivan et al., 2009). However, SLC9A3 mRNA in patients with ulcerative colitis, in spite of reduced NHE3 activity, was unchanged compared to controls (Yeruva et al., 2010). In addition based on immunofluorescence studies, there was no change in amount or distribution of NHE3 in DPPIV) (Girardi et al., 2001; Lee et al., 2010).
sigmoid colonic biopsies of patients with ulcerative colitis. Thus, the mechanism of the inflammation induced inhibition of NHE3 activity in IBD remains controversial. However, similarly to IBD, EPEC (enteropathogenic E. coli related) diarrhea, which causes small intestinal inflammation, was associated with reduced NHE3 (but increased NHE2 and NHE1) activity (Hecht et al., 2004). The EPEC inhibition of NHE3 required the bacteria’s type three secretion system and the bacterial virulence factor EspF, although how they contribute to the pathophysiology is not known.

The suggestion has been made, although without strong supporting data, that sudden infant death syndrome is associated with increased brainstem expression of NHE3. This is suggested to lead to a reduced respiratory drive. There was increased frequency of sudden infant death syndrome associated with the R799C NHE3 polymorphism as well as with two SLC9A3 promoter polymorphisms (G1131A and C1197T), although the study was criticized since controls were not age matched (Poetsch et al., 2010).

3.4. Slc9a4 – NHE4

Human NHE4 has 798 amino acids and is encoded by the SLC9A4 gene. The expression of NHE4 is highest in stomach and is also found although at lower levels in kidney medulla, hippocampus, zymogen granule of pancreas, and salivary gland. NHE4 localizes to the basolateral membrane of epithelial cells in these tissues where NHE1 also resides. In stomach, NHE4 is expressed in parietal cells. In kidney, NHE4 is found in macula densa cells, thick ascending limb and distal convoluted tubule, and to a lesser extent in collecting ducts and proximal tubules. In salivary gland, NHE4 is expressed in acinar and duct cells. However, NHE4 is not found in small and large intestine. When expressed in fibroblasts, NHE4 is virtually inactive but can be activated by cell shrinkage or by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid, an anion transporter inhibitor (Chambrey et al., 1997). NHE4 is relatively resistant to amiloride and its analogs.

The physiological function of NHE4 is not clear, although NHE4 knock-out mice have provided some insight into its physiological functions (Bourgeois et al., 2010; Gawenis et al., 2005). NHE4 does not appear to be involved in pH regulation of epithelial cells. In GI tract, Slc9a4 (−/−) mice are hypochlorhydric. Histological studies indicate that Slc9a4 (−/−) mice have reduced numbers of parietal cells, loss of mature chief cells; and increased number of undifferentiated cells as well as necrotic and apoptotic cells (Gawenis et al., 2005). Slc9a4 (−/−) parietal cells exhibit limited development of canalicular membranes and absence of tubulovesicles. Gawenis et al. suggest that basolateral NHE4 in parietal cells, functionally coupled with anion exchanger-2 (AE2, SLC4A2) is important for maintaining cell volume and intracellular ion concentrations for acid secretion (Gawenis et al., 2005). Slc4a2 knock-out mice are also achlorhydric (Gawenis et al., 2004). Consistent with this hypothesis, the cell volume of parietal cells from Slc9a4 (−/−) mice is reduced. In kidney, NHE4 is critical for NH4+/NH3 absorption in medullary thick ascending limb of Henle’s loop (TAL) where the apical Na/K/2Cl co-transporter (NKCC2, SLC12A1) is responsible for NH4+ absorption and the basolateral NHE4 is responsible for its exit (Eladari and Chambrey, 2010). This is supported by the observation that purified TAL basolateral membrane vesicles exhibit NHE activity which can function as a Na/NH4+ exchanger. Some of the ammonia that the TAL reabsorbs undergoes recycling by the descending thin limb of Henle’s loop (DTL), and the continuing NH4+/NH3 absorption and secretion by TAL and DTL, respectively, results in accumulation of ammonia in medullary interstitium (Eladari and Chambrey, 2010). This provides an effective gradient for ammonia excretion in distal tubule. Thus, when challenged with oral acid load, Slc9a4 (−/−) mice are unable to increase their urinary ammonium and net acid excretion and the lack of NHE4 prevents the medullary ammonia accumulation, resulting in metabolic acidosis and failure to increase urinary ammonium excretion. During chronic metabolic acidosis, NHE4 expression and activity are adaptively
increased in response to the increased demand for urinary excretion of $\text{NH}_4^+/\text{NH}_3$ (Bourgeois et al., 2010).

3.5. SLC9A5 – NHE5

Human NHE5 is encoded by the SLC9A5 gene, has 896 amino acids and its expression is highly restricted to brain and sperm. It is found in multiple regions of the brain including the dentate gyrus, cerebral cortex, hippocampus, amygdala, caudate nucleus, hypothalamus, subthalamic nucleus, and thalamus but not in glia-enriched structures such as the corpus callosum, suggesting that NHE5 might be neuron-specific. It has highest homology with NHE3 with about 50% in amino acid identity and shares similar pharmacological, regulatory and cell localization properties. Thus, NHE5 is located at both plasma membrane and recycling endosomes when expressed in mammalian cells and cycles between these two pools. The internalization of NHE5 is clathrin-mediated and forms a complex with $\beta$-arrestins (Lukashova et al., 2011; Szabo et al., 2005). $\beta$-arrestin-2 directly binds to the ser/thr-rich, di-isoleucine motif region in the C-terminus of NHE5 (amino acid 697–723) which is robustly phosphorylated by CK2 (Lukashova et al., 2011). Simultaneous mutation of the five Ser/Thr residues to Ala within NHE5 amino acids 702–714 abolished phosphorylation and binding of $\beta$-arrestin-2 in vitro. However, this mutant retained its ability to form a complex with $\beta$-arrestin-2 in vivo despite its lack of responsiveness. Additional mutations of two di-isoleucine-based motifs (I697A/L698A and I722A/I723A), either independently or together, disrupt this interaction. Thus, phosphorylation of NHE5 by CK2 is required for binding to $\beta$-arrestin-2 and for internationalization of NHE5 to recycling endosomes (Lukashova et al., 2011). On the other hand, the secretory carrier membrane protein, SCAMP2 shuttles NHE5 to the cell surface (Diering et al., 2009). SCAMP2 binds to NHE5 via both of its N- and C-terminal cytosolic domains and co-localizes with NHE5 predominantly in the recycling endosomes. Heterologous expression of SCAMP2 increases cell-surface abundance of NHE5 without affecting NHE5 internalization. Expression of a deletion mutant lacking the SCAMP2-specific N-terminal cytosolic domain or N-terminal cytosolic domain of SCAMP2 (amino acid 1–154) reduce the transporter activity. The small GTPases Arf6 and Rab11 regulate membrane traffic of NHE5 from recycling endosomes to the cell surface. The SCAMP2-mediated surface targeting of NHE5 is Arf6, but not Rab11 dependent. The dynamic distribution of NHE5 between plasma membrane and recycling endosomes is controlled by PI 3-K (exocytosis) and by the state of F-actin assembly (endocytosis). In addition to $\beta$-arrestins and SCAMP2, the N-terminus of receptor for activated C-kinase 1 (RACK1) directly binds to the C-terminus of NHE5 and positively regulates the transporter function (Onishi et al., 2007). RACK1 is a PKC interacting protein and scaffold protein that contains seven Trp-Asp (WD) repeats, each of which could independently interacts with other proteins. NHE5 co-localizes with RACK1, $\beta$1 integrin, paxillin and vinculin, markers of focal adhesions. Upon cell spreading which activates integrin-mediated signaling, RACK1 is recruited to the NHE5–integrin complex and perhaps stabilizes the complex. Knocking down RACK1 not only reverses integrin effects but also further lowers NHE5 activity. Thus, RACK1 regulates NHE5 via both integrin-dependent, and independent pathways. NHE5 might also be regulated by other kinases since in heterogenous expression of NHE5 in PS120 fibroblasts, NHE5 can be inhibited by protein kinase A, protein kinase C and hyperosmolarity (Attaphitaya et al., 2001).

The physiological functions of NHE5 were not known until recently. Numata et al. demonstrated that NHE5 acts as a negative regulator of dendritic spine growth which depends on NHE5 specific activity that regulates synaptic cleft pH (Diering et al., 2011). Enhanced neuronal activity targets NHE5 from endosomes to plasma membranes of dendritic spines. The increased activity of NHE5 results in alkalization of the dendritic spine and concomitant acidification of the synaptic cleft. This local acidification may serve
as an autocrine feedback mechanism that regulates pH-sensitive proteins at the postsynapse such as N-methyl D-aspartate receptors and possibly also as a paracrine mechanism to regulate presynaptic pH-sensitive proteins such as voltage gated Cl channels. Overexpression of NHE5 blocks spine growth in response to neuronal activity. Knockdown of Slc9a5, or expression of a dominant-negative Slc9a5 mutant (E209 mutant), results in spontaneous spine outgrowth. It is therefore suggested that NHE5 controls dendritic spine growth via a pH-dependent negative-feedback mechanism (Diering et al., 2011).

3.6. SLC9A6, SLC9A7 and SLC9A9 – Intracellular NHEs: NHE6, NHE7, NHE9

Nhx1, NHE6, NHE7, NHE9 are considered together as intracellular members of the NHE family derived evolutionarily from the S. cerevisiae Nhxl, the first member of this family molecularly identified (Nass et al., 1997). Nhxl is probably a model for the function of the other intracellular NHEs, and is a K\textsuperscript{+} and Na\textsuperscript{+}/H\textsuperscript{+} antiporter, that is present in the yeast vacuolar membrane where it serves to exchange intra vacuolar H\textsuperscript{+} for cytosolic K\textsuperscript{+} and thus sets the vacuolar and cytosolic pH and also appears to be involved in trafficking/fusion from the late endosome to the vacuole (Brett et al., 2005b). Nhxl appears to control both early steps of membrane trafficking from the late endosome to vacuole and fusion in the vacuole, effects dependent on intravacuolar pH. Abnormalities in these steps due to Nhxl KO could be reversed by correcting the vacuolar pH. In a cell free system, Nhxl was necessary for formation of multivesicular bodies acting to recruit Vps27, an ESCRT protein, to the endosomal membrane. While these results support the role of NHX1 as part of the ESCRT sorting pathway, a recent study showed, Nhxl was not necessary for multivesicular body formation, and suggested that Nhxl serves a role in endosomal membrane fusion downstream of the ESCRT pathway (Kallay L.M. et al., 2011).

NHE 6,7,9, encoded by the SLC9A6, SLC9A7 and SLC9A9 genes respectively, appear to have different localizations in intracellular organelles primarily along the endosomal and secretory pathways (Nakamura et al., 2005; Ohgaki et al., 2011); however, it is not known whether this is somewhat dependent on the functional state of the cell. The functions of these NHEs is thought mostly to set intraorganellar pHs at lesser acidity that generated by the V-ATPase in the organelar membranes with which they function in parallel; whether the functions of these NHEs are redundant is unclear. NHE6 is mostly considered a recycling endosomal protein (Brett et al., 2002), NHE7 trans-Golgi (Numata and Orlowski, 2001) and NHE9 late and recycling endosomes and late endosomes/lysosomes (Nakamura et al., 2005). NHE8 (encoded by SLC9A8), which is discussed separately, is present in mid to trans-Golgi, although it appears to be present in the BB of some epithelial cells. The basis for thinking these NHEs control organellar pH is that overexpression of each increased the intraorganellar pH in which they were primarily expressed (Nakamura et al., 2005). While these NHEs are present primarily in intracellular organelar membranes, in some cells they are present in other locations; for instance in vestibular hair bundles, NHE9 and less consistently NHE6 are present in the plasma membrane where they serve to remove cytosolic H\textsuperscript{+} in exchange for endolymph K\textsuperscript{+} (Hill et al., 2006). Tissue distribution of these NHEs is ubiquitous only for NHE9, with increased expression of NHE6 in brain and NHE7 in brain and skeletal muscle. Functionally the organellar NHEs exchange Na\textsuperscript{+} or K\textsuperscript{+} for intraorganellar H\textsuperscript{+} (in contrast to the plasma membrane NHEs which primarily exchange Na\textsuperscript{+} for H\textsuperscript{+}). It has been suggested that this difference in cation selectivity may be related to the presence of multiple charged residues at the putative second extracellular loop. The intraorganellar NHEs have similar V\textsubscript{max} and K\textsubscript{m} for Na\textsuperscript{+} and K\textsuperscript{+}.

NHE6, is present primarily in the recycling endosomes but a minor component is also present in the plasma membrane, for instance in vestibular hair bundles, adipocytes, fibroblasts and likely many other cells and it has a major plasma membrane distribution in a few specialized cells; for instance in the basolateral membrane of osteoblasts, particularly in
areas of high mineralization, where it helps to remove the high H⁺ load produced by mineralization. Another function of NHE6 was demonstrated in hepatoma HepG2 cells which express a splice variant of Slc9a6 (NHE6.1). Knock down of NHE6.1 lowered recycling endosomal pH and surprisingly disrupted the apical canalicular plasma membrane including failure to traffick or maintain apical proteins; these effects were associated with reduced amounts of apical lipids and suggests an effect of NHE6 in regulating apical recycling that involves lipids as well as proteins. However, in other cell models, knocking down NHE6 did not alter endosomal pH while knocking down NHE9 in addition did lead to acidification of early endosomes, suggesting either was sufficient for the pH regulation. In addition, based on knock down studies, NHE6 has a role in clathrin dependent endocytosis in HeLa cells by acidifying clathrin containing endocytic vesicles; NHE6 co-localizes with clathrin and knocking it down inhibits early steps in transferrin endocytosis but not that of substrates endocytosed by non-clathrin dependent mechanisms (cholera toxin B subunit and EGF) (Xinhan L. et al., 2011).

Regulation of the intracellular NHEs has been incompletely studied. However, NHE6 (as well as NHE7 and 9) bind RACK1, using the NHE cytoplasmic C-terminus. Knocking down RACK1 led to more intracellular and less plasma membrane NHE6 and was accompanied by higher pH in the recycling endosomes (Ohgaki et al., 2008). This suggests there is regulated trafficking of NHE6 between the plasma membrane and recycling endosomes that is RACK1 dependent and that this balance affects the intracellular pH of the recycling endosome.

NHE6 and NHE7 have multiple additional C-terminal binding partners (cytosolic proteins); however, the functions of which relating to regulation of these NHEs are poorly understood. NHE7 binds SCAMPS, involved in vesicle trafficking, calmodulin which binds multiple other plasma membrane NHEs, caveolin, CD44, and most intriguingly GLUT1 (Lin et al., 2005; Kagami et al., 2008). This is another area in which these NHEs are similar to plasma membrane NHEs, especially NHE1, NHE3 and NHE5, with identification of the binding partners of the intraorganellar NHEs just beginning.

NHE7 appears to be the NHE isoform present in the trans-Golgi, although it also trafficks to the recycling system and to the plasma membrane (Numata and Orlowski, 2001). As with other NHEs, it is partially localized to lipid rafts and associates with caveolin. The NHE7 C-terminus was responsible for its trans-Golgi localization compared to NHE6, but NHE6 localization to the recycling system could not be attributed to the NHE6 C-terminus. An unusual feature of NHE7 is its insensitivity to amiloride, while it is inhibited by benzamil and quinine.

Diseases of the intracellular NHEs: in keeping with importance of maintenance of organellar pH, multiple neurological syndromes have been associated with consequences of disrupting functions of the intracellular NHEs, particularly NHE6 and NHE9 (Morrow et al., 2008; Gilfillan et al., 2008; Takahashi et al., 2011; Yasuda et al., 2011; Roxrud et al., 2009). The specific associations include: SLC9A9 mutations are possibly involved in familial autism although some studies did not find an association and there is also a possible association with attention deficit hyperactivity disorder; SLC9A6: multiple cases of X-linked mental retardation resembling Angelman syndrome and Christianson sub type have had truncation, deletion, point mutations and exon skipping of NHE6. While expressed in neurologic tissues in significant amounts, how mutations in SLC9A6 and SLC9A9 lead to neurologic disorders is not known, although it has been suggested that these mutations lead to failure to establish normal polarity or that the mutations altered vesicle trafficking by altering cytoskeleton interactions of NHE6.
3.7. SLC9A8 –NHE8

The SLC9A8 gene encodes human NHE8 which has 581 amino acids, and its message is ubiquitously expressed in mouse and human tissues with highest expression in skeletal muscle and kidney. From a phylogenetic analysis of mammalian SLC9s, SLC9A8 was predicted to encode an intracellular NHE and shares about 25% homology with other members of the gene family (Brett et al., 2005a). Furthermore, the C-terminus of NHE8 is 50–100 amino acids shorter than other NHEs and shares no significant amino acid similarity, suggesting that the regulation of NHE8 is different from other members. Indeed, NHE8 is an intracellular NHE in mosquito Malpighian tubules (Kang’ethe et al., 2007). When expressed in mammalian CHO and HeLa cells, it is localized primarily to mid- to trans-Golgi and to a lesser extent to endosomes (Nakamura et al., 2005). Silencing NHE8 in HeLa-M cells results in perinuclear clustering of endosomes and lysosomes and perturbs endosomal protein trafficking. Bowers et al. suggest that NHE8 might be a negative regulator of inward vesiculation or NHE8 might promote back fusion (Lawrence et al., 2010). These processes are driven by endosomal pH, the steady-state of which is maintained by vacuolar ATPase and intracellular organelle NHEs (Lawrence et al., 2010).

In addition to its intracellular location, NHE8 is localized to the apical membrane of renal proximal tubule and intestine. In kidney, NHE8 is restricted to the proximal tubules whereas in intestine, NHE8 is found in stomach, duodenum, jejunum, ileum and colon. Both NHE3 and NHE8 are developmentally regulated with NHE8 being the major intestinal brush border NHE in neonates and NHE3 being the predominant brush border NHE in adults (Xu et al., 2008; Becker et al., 2007). In neonatal rat proximal tubules, there is considerably NHE activity despite the amount of NHE3 protein being low. The presence of NHE activity in proximal tubules of Slc9a2/Slc9a3 double knock-out mice raised the possibility of the presence of an additional brush border NHE other than NHE2 and NHE3 which mediates renal acidification (Choi et al., 2000; Xu et al., 2011). There appears to be compensatory up-regulation of intestinal NHE8 in Slc9a2/Slc9a3 double knock-out mice and this up-regulation of NHE8 appears to be gender dependent (Xu et al., 2011). The signal for the developmental NHE expression switch is unclear but is coincident with perinatal increase in serum glucocorticoids and thyroid hormones. Baum et al. demonstrated that the abundance of NHE3 protein and message in renal proximal tubules of neonatal animals can be increased by administering either glucocorticoids or thyroid hormones. Alternatively, administration of thyroid hormone to neonates before the normal increase that occurs at weaning results in a premature decrease in brush border NHE8 protein abundance. Conversely, high levels of brush border NHE8 persist into adulthood in hypothyroid rats (Gattineni et al., 2008). Similarly, the expression of Slc9a8 mRNA and protein in intestine is decreased in glucocorticoid-treated animals whereas Slc9a3 mRNA and protein are up-regulated (Xu et al., 2010).

Although NHE3 is the major renal and intestinal brush border NHE in adults, NHE8 appears also to contribute to Na absorption in these adult tissues although results are not definitive. Decreased expression of NHE8 protein and message is associated with defective acidification in proximal convoluted tubules of aged rats (Fiori et al., 2009). In intestinal inflammation, both NHE3 and NHE8 are decreased, accounting for reduction of Na absorption in inflammatory diarrhea. Somatostatin stimulates NHE8 but not NHE3 expression in the mouse intestine (Wang et al., 2011). While brush border NHE activity is decreased in patients with congenital Na diarrhea, there is no identified exonic mutation in SLC9A3 or SLC9A8 in these patients (same for SLC9A1/2/5) leaving the inhibited NHE activity in this condition not understood (Baum et al., 2011).

Is NHE8 an intracellular NHE or a plasma membrane NHE? Expression of exogenous NHE8 in CHO and HeLa cells results in intracellular localization but its expression in
PS120 fibroblasts allows sufficient amount of surface NHE8 protein for functional characterization (Xu et al., 2008). In rat renal proximal tubules, the brush border NHE8 protein decreases upon maturation but the total amount of NHE8 in renal cortical membranes is higher in the adult compared to the neonate and there is no change in the amount of Slc9a8 message (Becker et al., 2007). These findings suggest that a substantial amount of NHE8 is intracellular in adult proximal tubules. Immunostaining of adult proximal tubules with NHE8 antibodies also shows that it is in the coated pit regions in addition to brush borders (Goyal et al., 2005). Therefore, while NHE8 resides on the brush border of intestine and renal proximal tubules in neonates, it is predominantly intracellular upon maturation of animals, at least in renal proximal tubules. What governs the steady-state plasma membrane and intracellular expression of NHE8 remains to be determined.

4. SLC9B/NHA family

The SLC9B exchangers have recently been added to the SLC9 family. Brett and coworkers used a bioinformatics approach to identify a previously unrecognized family of NHEs that were present in all completely sequenced metazoan genomes (Brett et al., 2005a,b). Compared to NHE isoforms 1–9, these newly identified NHEs had higher homology to prokaryotic NHEs, like the E.coli NhaA, and were thus named NHA1 (encoded by SLC9B1; also called NHEDC1) and NHA2 (encoded by SLC9B2; also called NHEDC2), respectively. In the species-independent monovalent cation/proton antiporter (CPA) classification, NHA1 and NHA2 belong to the CPA2 family. NHAs are predicted to contain 12 transmembrane domains, but unlike NHEs1–9, seem to possess only short intracellular N- and C-termini.

The 515 amino acid long NHA1 was cloned in 2006 (Ye et al., 2006). The protein is ~50 kDa when transiently overexpressed in CHO cells and based on RT-PCR experiments of human RNA tissue samples, exclusively expressed in testis. The Drosophila melanogaster homologues of NHA1 and NHA2, CG10806 and CG31052, localize to the apical plasma membrane of Malpighian (renal) tubules, together with the proton pumping V-ATPase (Day et al., 2008). Overexpression of CG10806 but not CG31052 in Malpighian tubular cells conferred higher basal but lower stimulated fluid secretion; while overexpression of CG31052 enhanced tubular secretion of K⁺ and Na⁺. Upon heterologous expression in NHE-deficient yeast S. cerevisiae, CG10806 localized to the plasma membrane and conferred protection against excess K⁺. Heterologously overexpressed CG31052 on the other hand was present on the vacuolar membrane and transformed yeast displayed increased tolerance towards excess Na⁺. The biologic function of NHA1 remains unclear and SLC9B1 has not been linked to human disease.

More progress has been made in studies on the closely related NHA2 isoform. Battaglino and coworkers first identified and cloned SLC9B2 by a microarray approach conducted to identify genes upregulated in receptor-activation of NF-κB ligand (RANKL)-stimulated osteoclast precursor cells (Battaglino et al., 2007). SiRNA-mediated knock-down significantly inhibited osteoclast differentiation and osteoclast function in vitro. Xiang and co-workers showed that NHA2 was a ubiquitously expressed protein of ~50 kDa in mouse tissues (Fuster et al., 2008; Xiang et al., 2007). Based on immunofluorescence studies of pancreatic β-cells (INS-1), distal tubular cells of the kidney (MDCK) and NHE-deficient yeast heterologously expressing human NHA2, NHA2 was proposed to be a plasmalemmal NHE. When expressed in NHE-deficient yeast, NHA2 conferred tolerance to Li⁺ and Na⁺ but not K⁺, in a pH-dependent manner (Fuster et al., 2008; Xiang et al., 2007). NHA2 was inhibited by phloretin but not by the NHE-inhibitor amilorde, even at high concentrations. Mutation of two conserved aspartic acid residues in the putative transmembrane domain 5 of NHA2 led to loss of salt tolerance in transfected yeast (Xiang et al., 2007). These functional complementation studies in yeast strongly supported that NHA2 was a bona fide NHE.
However, no direct kinetic evidence exists up to now, that NHAs act as cation/H\(^+\) exchangers. Due to chromosomal localization, inhibitor characteristics, transport properties and its presence on the erythrocyte membrane, NHA2 was proposed to be the long sought Na\(^+\)/Li\(^+\) countertransporter (SLC), that has been linked to the pathogenesis of essential hypertension in humans (Xiang et al., 2007). In support of this hypothesis, Moe and coworkers found NHA2 to be expressed in the distal tubule of rat kidney, a renal tubular segment that is paramount for Na\(^+\) and blood pressure homeostasis in mammals (Fuster et al., 2008).

Recently, the bone phenotype of a Slc9b2-deficient mouse was published (Hofstetter et al., 2010). Surprisingly, in contrast to published in vitro evidence reviewed above, Slc9b2-deficient mice had normal bone density and structural parameters of bone, quantified by high-resolution microcomputed tomography, were not different in Slc9b2-deficient mice compared to wild-type mice. In addition, in vitro RANKL stimulation of bone marrow cells isolated from wild-type and Slc9b2-deficient mice yielded no differences in osteoclast development and activity. Endogenous NHA2 was present both intracellularly and on the basolateral membrane of RAW 267.4 and bone marrow derived osteoclasts. Intracellularly, NHA2 co-localized with endosomal and lysosomal markers but not with mitochondrial markers. These findings suggested that NHA2 was dispensable for osteoclast differentiation and bone resorption both in vitro and in vivo. At the present time, the reason for the discrepancy between the finding of this study with genetic Slc9b2 deficiency and earlier studies using siRNA-mediated knockdown of Slc9b2 remain unclear. Thus, at the present time, the biological role and transport kinetics of NHA2 remain unknown and the subcellular localization of NHA2 remains controversial.

5. SLC9C/sperm NHEs

The Slc9c1 gene encoding sperm-specific NHE was originally identified by Garbers and coworkers in a mouse spermatid (haploid cell) enriched cDNA library (Wang et al., 2003, 2007). Mammalian SLC9Cs lack distinct orthologs in non-mammalian genomes, and encode an NHE-like N-terminal domain and a long non-conserved C-terminal part with similarity to the Na-transporting carboxylic acid decarboxylase transporter family (NaT-DC), a subfamily of the CPA superfamily (Brett et al., 2005a,b). Sperm NHE was thus grouped apart from NHEs (SLC9A family) and NHAs (SLC9B family) into a new SLC9C subfamily. Slc9c1 mRNA expression was restricted to testicular tissue by Northern blotting and dot-blot analysis of a wide array of mouse tissues (Wang et al., 2003). The putative open reading frame of mouse Slc9c1 encodes 1120 amino acids. Based on hydropathy analysis, the protein is proposed to contain 14 transmembrane domains, which includes a unique voltage-sensing motif and a cyclic nucleotide-binding domain (Wang et al., 2003). When transfected in NHE-null fibroblasts, full length sperm NHE expressed poorly. A chimeric construct with the first transmembrane domain of sperm NHE replaced by that of NHE1, however, exhibited improved expression at the plasma membrane and measurable NHE activity, suggesting that sperm NHE is indeed a functional NHE. Slc9c1-null males are completely infertile with severely diminished sperm motility but normal sperm numbers and sperm morphology (Wang et al., 2003). A sperm NHE-specific polyclonal antibody detected a ~130 kDa protein on Western blot in testicular lysates of wild-type but not Slc9c1 knock-out mice. Addition of ammonium chloride and cell-permeant cAMP analogues partially rescued the motility and fertility defects. Knock-out of sperm NHE results in a complete loss of full length bicarbonate-sensitive soluble adenylate cyclase (sAC) with greatly reduced bicarbonate-stimulated soluble adenyllyl cyclase activity (Wang et al., 2007). sAC and sperm NHE interact physically with each other, composing a signaling complex at the sperm flagellar plasma membrane that seems to be vital for control of intracellular bicarbonate and
cAMP levels, both of which are of great importance for sperm capacitation and motility. Although a likely candidate, sperm NHE has not been linked to male infertility in humans.

SLC9C2 (also known as NHE11) is another member of the SLC9C family for which no functional data exist. Based on EST databases it is expressed in testis and probably also present in ovary, skin and connective tissue.

6. Summary

Future progress in understanding of the SLC9 gene family, which currently is undergoing increased understanding of structure and function relationships and increased insights in regulation normally and in models of disease, is likely to include insights into the pathophysiology of multiple diseases. We predict that therapies for these diseases as well as other medical conditions will be approachable by altering SLC9 gene family function including by use of drugs and peptides that mimic normal regulation of these proteins.

Acknowledgments

We apologize to the many investigators whose work could not be quoted and/or referenced due to space contraints. National Institutes of Health, NIDDK Grants RO1-DK26523, RO1-DK061765, PO1-DK072084, and R24-DK04388 (The Hopkins Basic Research Digestive Diseases Development Core Center), and the Hopkins Center for Epithelial Disorders; Swiss National Science Foundation grant (# 3100A0-117732), the Swiss National Centre of Competence in Research (NCCR TransCure), the Novartis Research Foundation, and by a Medical Research Position Award of the Foundation Prof. Dr. Max Cloëtta.

References


Lukashova V, Szabo EZ, Jinadasa T, Mokhov A, Litchfield DW, Orlowski J. CK2 phosphorylation of an acidic Ser/Thr di-isoleucine motif in the Na\(^+\)/H\(^+\) exchanger NHE5 isoform promotes


Mol Aspects Med. Author manuscript; available in PMC 2013 July 26.


Fig. 1.
Human sequences of SLC9 family were aligned using COBALT (Papadopoulos and Agarwala, 2007), a constraint-based alignment tool for multiple protein sequences. For NHE6, NHA1 and sperm-NHE which have spliced variants, the longest spliced variant (v1) is used for alignment. The radial tree was drawn by Drawtree.
Fig. 2.
(a) Model of the transport domain of NHE1 showing the area of exchange as two opposing funnel structures facing the intracellular and extracellular surfaces with membrane spanning domains indicated by roman numerals with critical amino acids shown. (b) Comparison of NhaA and NHE1 transport domains, modeled from the crystal structure of NhaA. The homologous amino acids crucial to exchange of NhaA and NHE1 are show. (With permission from Donowitz et al., 2009, orginally from Landau et al., 2007)
Table 1

SLC 9 family of Na\(^+\)/H\(^+\) exchangers\(^c\). For detailed information about the SLC gene tables, please visit: http://www.bioparadigms.org.

<table>
<thead>
<tr>
<th>Human gene name</th>
<th>Protein name</th>
<th>CPA subfamily</th>
<th>Number of aa.*</th>
<th>Substrates</th>
<th>Human disease</th>
<th>Knock-out mice phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLC9A1</td>
<td>NHE1</td>
<td>CPA1</td>
<td>815</td>
<td>Na(^+), Li(^+), H(^+), NH(_4^+)</td>
<td>Ataxia, growth retardation, seizures, slow-wave epilepsy, increased neuronal excitability, resistant to cardiac ischemia–reperfusion injury and premature death</td>
<td></td>
</tr>
<tr>
<td>SLC9A2</td>
<td>NHE2</td>
<td>CPA1</td>
<td>812</td>
<td>Na(^+), Li(^+) H(^+), NH(_4^+)</td>
<td>Reduced viability of gastric parietal cells, hypochlorhydria, increased renal renin content, impaired recovery of intestinal barrier function</td>
<td></td>
</tr>
<tr>
<td>SLC9A3</td>
<td>NHE3</td>
<td>CPA1</td>
<td>834</td>
<td>Na(^+), Li(^+), H(^+), NH(_4^+)</td>
<td>Congenital Na diarrhea; Sudden infant death syndrome</td>
<td></td>
</tr>
<tr>
<td>SLC9A4</td>
<td>NHE4</td>
<td>CPA1</td>
<td>798</td>
<td>Na(^+), Li(^+) (?), H(^+), NH(_4^+)</td>
<td>Stomach inflammation, hypochlorhydria, gastric necrosis. Defective in ammonium/ammonia absorption in renal thick ascending limb</td>
<td></td>
</tr>
<tr>
<td>SLC9A5</td>
<td>NHE5</td>
<td>CPA1</td>
<td>896</td>
<td>Na(^+), Li(^+), H(^+), NH(_4^+) (?)</td>
<td>Mild-diarrhea, acidosis, impaired acid–base balance and Na—fluid volume homeostasis in kidney and intestine. Spontaneous distal colitis due to luminal bacteria</td>
<td></td>
</tr>
<tr>
<td>SLC9A6</td>
<td>NHE6</td>
<td>CPA1</td>
<td>701 (v1) 669(v2) 69(v3)</td>
<td>Na(^+), K(^+), H(^+)</td>
<td>X-linked Mental Retardation (Angelman Syndrome and Christianson Subtype). Epilepsy and ataxia</td>
<td></td>
</tr>
<tr>
<td>SLC9A7</td>
<td>NHE7</td>
<td>CPA1</td>
<td>725</td>
<td>Na(^+), K(^+), Li(^+), H(^+), NH(_4^+) (?)</td>
<td>Hyper-reactivity, increased susceptibility to pharmacologically induced seizures</td>
<td></td>
</tr>
<tr>
<td>SLC9A8</td>
<td>NHE8</td>
<td>CPA1</td>
<td>581</td>
<td>Na(^+), K(^+), H(^+)</td>
<td>Familial Autism; Attention Deficit Hyperactivity Disorder</td>
<td></td>
</tr>
<tr>
<td>SLC9A9</td>
<td>NHE9</td>
<td>CPA1</td>
<td>645</td>
<td>Na(^+), K(^+), H(^+)</td>
<td>Essential hypertension (?)</td>
<td></td>
</tr>
<tr>
<td>SLC9B1</td>
<td>NHA1 (NHEDC1)</td>
<td>CPA2</td>
<td>515 (v1) 475(v2)</td>
<td>Na(^+), Li(^+)</td>
<td>Infertile male, asthenozoospermia</td>
<td></td>
</tr>
<tr>
<td>SLC9B2</td>
<td>NHA2 (NHEDC2)</td>
<td>CPA2</td>
<td>537</td>
<td>Na(^+), Li(^+)</td>
<td>Infertile male, asthenozoospermia</td>
<td></td>
</tr>
<tr>
<td>SLC9C1</td>
<td>Sperm-NHE</td>
<td>NaT-DC</td>
<td>1177 (v1) 1129(v2)</td>
<td>Na(^+), H(^+)</td>
<td>Infertile male, asthenozoospermia</td>
<td></td>
</tr>
<tr>
<td>SLC9C2</td>
<td>NaT-DC</td>
<td></td>
<td>1124</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Human

\(^b\) v = variant

\(^c\) Human SLC9 family is a subgroup of the monovalent cation proton antiporter (CPA) superfamily as described by Brett et al. (2005a,b). The human SLC9A is part of CPA1 family and the human SLC9B is part of CPA2 family. The human SLC9C is weakly associated with NaT-DC (Na-transporting carboxylic acid decarboxylase) family.